1 / 1
Ipamorelin is a synthetic pentapeptide growth hormone releasing peptide (GHRP) composed of five amino acids (Aib-His-D-2-Nal-D-Phe-Lys-NH₂). It is a selective GHSR-1a agonist with the ability to stimulate growth hormone (GH) secretion with high specificity.
Compared with earlier GHRPs (such as GHRP-2 and GHRP-6), Ipamorelin shows better selectivity, safety and pharmacological stability without significantly affecting the levels of other hormones such as cortisol, prolactin or ACTH.
As a highly-regarded peptide API, Ipamorelin is currently widely used in anti-aging research, sports rehabilitation, osteoporosis intervention, postoperative recovery and metabolic function regulation.
Ipamorelin promotes the release of endogenous growth hormone (GH) from the anterior pituitary by selectively activating the growth hormone secretion receptor (GHSR-1a) and mimicking the action of ghrelin. Its main pharmacological mechanisms include:
Ipamorelin highly selectively excites GHSR-1a, prompting the pituitary gland to release GH without significantly affecting ACTH or cortisol levels, offering better endocrine safety.
By increasing IGF-1 levels, it promotes muscle cell anabolism, enhances tissue repair and regeneration, and is suitable for trauma repair, surgical recovery, and anti-muscle atrophy treatment.
GH has the effects of fat mobilization and insulin sensitivity improvement. Ipamorelin assists in regulating metabolic status and is used in research on metabolic syndrome and obesity intervention.
The GH/IGF-1 axis promotes bone formation and mineralization. Ipamorelin shows promise in anti-osteoporosis, fracture rehabilitation, and anti-aging research.
GH release is usually accompanied by deep sleep. Studies have found that Ipamorelin can indirectly improve sleep structure and enhance physiological recovery ability.
Although still in the preclinical/early clinical stage, Ipamorelin has shown good safety and efficacy in animal and select human studies:
In addition, Ipamorelin combined with other GHRH mimetics (such as CJC-1295) in some studies showed synergistic effects, further enhancing the pulse release of GH.
The Ipamorelin API is prepared using high-standard solid phase peptide synthesis process (SPPS), strictly purified and quality tested, suitable for scientific research and development as well as early pipeline use of pharmaceutical companies.
